Javier Ariza - Infectious Diseases

Author Information

Javier Ariza is an esteemed researcher in the field of Infectious Diseases, currently affiliated with the Department of Infectious Diseases at Hospital Universitari Bellvitge in Barcelona, Spain. His work primarily focuses on infectious complications related to osteoarticular infections and the management of prosthetic joint infections.

Research Contributions

Javier Ariza has made significant contributions to the understanding and management of infectious diseases, particularly in the context of osteoarticular infections and prosthetic joint complications. His research encompasses the study of antibiotic therapies, including the effectiveness of suppressive antibiotic therapy, and the pharmacokinetics of continuous antibiotic infusions. He has extensively investigated infections caused by multidrug-resistant organisms, including various studies on Pseudomonas aeruginosa. His work is crucial in improving treatment outcomes for complex infections associated with medical implants and resistant bacteria.

Aliases

Javier Ariza is also known by several aliases in academic publications, including J Ariza, J. Ariza, and J. X. Ariza. These variations may appear across different research publications and databases.

Publication and Citation Metrics

Metric	Value
Total Citations	10,716
H-index	58
Total Papers	213

Publications:

Implant Removal in the Management of Prosthetic Joint Infection by Staphylococcus aureus: Outcome and Predictors of Failure in a Large Retrospective Multicenter Study

DOI: 10.3390/antibiotics10020118

Year: 2021

Correction to: The biological tests used in acute-phase of inflammation in bone infection Clinical study

DOI: 10.1007/s00590-021-02973-7

Year: 2021

Risk Factors of Daptomycin-Induced Eosinophilic Pneumonia in a Population with Osteoarticular Infection

DOI: 10.3390/antibiotics10040446

Year: 2021

Infections after spine instrumentation: effectiveness of short antibiotic treatment in a large multicentre cohort.

DOI: 10.1093/jac/dkaa548

Year: 2021

In vitro pharmacokinetics/pharmacodynamics of continuous ceftazidime infusion and its combination with colistin against Pseudomonas aeruginosa biofilm.

DOI: 10.1016/j.ijantimicag.2020.106246

Year: 2020

Efficacy and Therapeutic Drug Monitoring of Continuous Beta-Lactam Infusion for Osteoarticular Infections Caused by Fluoroquinolone-Resistant Pseudomonas aeruginosa: A Prospective Cohort Study

DOI: 10.1007/s13318-020-00625-5

Year: 2020

Suppressive antibiotic therapy in prosthetic joint infections: A multicentre cohort study.

DOI: 10.1016/j.cmi.2019.09.007

Year: 2019

MULTIDRUG- AND EXTENSIVELY DRUG-RESISTANT GRAM-NEGATIVE OSTEOSYNTHESIS-ASSOCIATED OSTEOMYELITIS OF THE LOWER EXTREMITIES: A MULTICENTRE INTERNATIONAL STUDY (on behalf of the ESGIAI)

DOI:

Year: 2019

Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model.

DOI: 10.1016/j.ijantimicag.2019.01.010

Year: 2019

The Impact of Gram-Negative Bacilli in Bacteremic Skin and Soft Tissue Infections Among Patients With Diabetes

DOI: 10.2337/dc18-2294

Year: 2019

What are Stool Samples?

What Happens After the Biopsy?

What are Healthcare Associated Infections (HAIs)?

What are the challenges associated with DAAs?

How Can it be Prevented?

Why is Antimicrobial Resistance a Concern?

How Can Hygiene Practices be Implemented in Healthcare Settings?

How Can We Improve Vaccination Rates?

How Does WHO Address Infectious Diseases?

What is a Retrovirus?

Partnered Content Networks

Relevant Topics